Results 221 to 230 of about 1,013,409 (339)

Changes in Protein Expression of Renal Drug Transporters and Drug‐Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Autosomal dominant polycystic kidney disease is the most prevalent inherited kidney disease and leads to bilateral kidney enlargement and progressive loss of renal function, often over decades. Comorbidities include hypertension, flank pain, and bacterial infections. The condition often necessitates prolonged multidrug therapy.
Annika C. Tillmann, Dorien J. M. Peters, Amin Rostami‐Hodjegan, Patricia Wilson, Jill Norman, Jill Barber, Zubida M. Al‐Majdoub   +6 more
wiley   +1 more source

Disparities in heart transplant survival and graft rejection outcomes persist in the modern era: a call to race towards a more equitable future. [PDF]

Eur J Cardiothorac Surg
Firoz A, Remer D, Zhao H, Lu X, Hamad E.
europepmc   +1 more source

Challenges in Assessing COVID-19 Vaccines Safety Signals-The Case of ChAdOx1 nCoV-19 Vaccine and Corneal Graft Rejection. [PDF]

Vaccines (Basel), 2023
Bizimungu C, Sabbe M, Wuillaume F, Hamdani J, Koch P, Dogné JM.   +5 more
europepmc   +1 more source

THE ROLE OF MHC AND NON-MHC ANTIGENS IN THE REJECTION OF INTRACEREBRAL ALLOGENEIC NEURAL GRAFTS

, 1989
Kanchan Rao, Raymond D. Lund, Heinz W. Kunz, Thomas J. Gill   +3 more
openalex   +1 more source

IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. [PDF]

, 1997
Regula Mueller, Joanna D. Davies, Troy Krahl, Nora Sarvetnick   +3 more
openalex   +1 more source

Microbiome‐Informed Dosing: Exploring Gut Microbial Communities Impact on Mycophenolate Enterohepatic Circulation and Therapeutic Target Achievement

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF).
Abdelrahman Saqr, Shen Cheng, Mahmoud Al‐Kofahi, Christopher Staley, Pamala A. Jacobson   +4 more
wiley   +1 more source

Local delivery of FK506 to a nerve allograft is comparable to systemic delivery at suppressing allogeneic graft rejection. [PDF]

PLoS One, 2023
Davis B, Wojtalewicz S, Erickson S, Veith J, Simpson A, Sant H, Shea J, Gale B, Agarwal J.   +8 more
europepmc   +1 more source

REGULATION OF CYTOTOXIC T LYMPHOCYTE-MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW

, 1988
Barbara E. Bierer, Stephen G. Emerson, Joseph H. Antin, Richard T. Maziarz, Joel M. Rappeport, Brian R. Smith, and Steven J. Burakoff   +6 more
openalex   +1 more source

Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations

Clinical Pharmacology &Therapeutics, EarlyView.
Busulfan is administered intravenously in conditioning regimens prior to allogeneic hematopoietic stem cell transplantation (HSCT), with model‐informed precision dosing (MIPD) targeting a 4‐day cumulative AUC of 80–100 mg*hour/L. Three pharmacokinetic (PK) models—Bognar, Langenhorst, and McCune—were evaluated using data with a minimum of 1 and a median
Rashudy F. Mahomedradja, Tim Bognàr, Kaj E. van Schie, Ilse T. Kuipers, Moniek A. de Witte, Jurgen H.E. Kuball, Erfan Nur, Bram J. Wilhelm, Marise R. Heerma van Voss, Linda Franken, Arief Lalmohamed, Eleonora (Noortje) L. Swart, Dave C. de Leeuw, Imke H. Bartelink   +13 more
wiley   +1 more source

Overcoming Graft Rejection in Induced Pluripotent Stem Cell-Derived Inhibitory Interneurons for Drug-Resistant Epilepsy. [PDF]

Brain Sci
Beaudreault CP, Wang R, Muh CR, Rosenberg A, Funari A, McGoldrick PE, Wolf SM, Sacknovitz A, Chung S.   +8 more
europepmc   +1 more source